Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: External validation of a prognostic score

Tumor Biology

Volumn 29, Issue 4, 2008, Pages 272-277

  Blankenburg, Florian ^a   Hatz, Rudolf ^a   Nagel, Dorothea ^a   Ankerst, Donna ^c   Reinmiedl, Judith ^b   Gruber, Christine ^a   Seidel, Dietrich ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Centre for Pneumology and Thoracic Surgery   (Germany)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

CEA; CYFRA 21 1; External validation; Non small cell lung cancer; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; SURVIVAL RATE;

EID: 51049102813     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000152945     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Wittekind Ch, Meyer H-J, Bootz F (eds): UICC: TNM Classification of Malignant Tumours, ed 6. Berlin, Springer, 2002.
4. Smythe WR: Treatment of stage I non-small cell lung carcinoma. Chest 2003;123:181S-187S.
5. Tsuboi M, Ohira T, Saji H, et al: The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer (review). Ann Thorac Cardiovasc Surg 2007;13:73-77.
6. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
7. Muley T, Dienemann H, Ebert W: CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 2004;24:1953-1956.
8. World Health Organization: Histological Typing of Lung Tumours, ed 2. Geneva, World Health Organization, 1981.
9. Mountain CF: Revisions in the international item for staging lung cancer. Chest 1997;111:1710-1717.
10. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-835.
11. Alam N, Darling G, Evans WK, Mackay JA, Shepherd FA: Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol 2006;58:146-155.
12. Booth CM, Shepherd F: Adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2006;1:180-187.
13. Muley T, Dienemann H, Ebert W: Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 2003;23:4085-4093.
14. Harpole DH, Herndon JE, Young WG, Wolfe WG, Sabiston DC: Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-796.
15. Nesbitt JC, Putnam JB, Walsh GL, Roth JA, Mountain CF: Survival in early stage non-small cell lung cancer. Ann Thorac Surg 1995;60:466-472.
16. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
17. Suzuki H, Ishikawa S, Satoh H, et al: Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:648-652.
18. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N: Prognostic value of carcinoembryonic antigen and CYFRA 21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surgy 2007;32:435-439.
19. Stieber P, Hasholzner U, Bodenmuller H, et al: CYFRA 21-1. A new marker in lung cancer. Cancer 1993;72:707-713.
20. Nisman B, Lafair J, Heching N, et al: Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998;82:1850-1859.
21. Pujol J-L, Molinier O, Ebert W, et al: CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004;90:2097-2105.
22. Pujol JL, Boher JM, Grenier J, Quantin X: CYFRA 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001;31:221-231.
23. Nisman B, Amir G, Lafair J, et al: Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999;19:3549-3552.
24. Kulpa J, Wójcik E, Reinfuss M, Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-1937.
25. Sawabata N, Ohta M, Takeda S, et al: Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 2002;74:174-179.
26. Suzuki K, Nagai K, Yoshida J, et al: Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 1999;67:927-932.
27. Koike T, Tsuchiya R, Goya T, Sohara Y, Miyaoka E: Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol 2007;2:408-413.
28. Kobayashi N, Toyooka S, Soh J, et al: Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. J Thorac Oncol 2007;2:808-812.
29. Reinmuth N, Brandt B, Semik M, et al: Prognostic impact of CYFRA 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002;36:265-270.
30. Tsuchiya T, Akamine S, Muraoka M, et al: Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007;56:341-348.